

To Rhona, Hannah, Douglas, Alice, Kathleen and Euan for being a great family,
and especially to Fiona for her support during this and many other projects (LK)

To Indrani and Ishani (AB)

Problem Solving in Endocrinology and Metabolism

Lee Kennedy

James Cook University, Queensland, Australia

Ansu Basu

City Hospital, Birmingham, UK

CLINICAL PUBLISHING

OXFORD

CLINICAL PUBLISHING

An imprint of Atlas Medical Publishing Ltd

Oxford Centre for Innovation
Mill Street, Oxford OX2 0JX, UK

T: +44 1865 811116

F: +44 1865 251550

W: www.clinicalpublishing.co.uk

Distributed in the USA and Canada by:

Clinical Publishing
30 Amberwood Parkway
Ashland OH 44805 USA

T: 800 247 6553 (toll free within U.S. and Canada)

F: 419 281 6883

E: order@bookmasters.com

Distributed in UK and Rest of World by:

Marston Book Services Ltd
PO Box 269, Abingdon
Oxon OX14 4YN, UK

T: +44 1235 465500

F: +44 1235 465555

E: trade.orders@marston.co.uk

©Atlas Medical Publishing Ltd 2007

First published 2007

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Clinical Publishing or Atlas Medical Publishing Ltd

Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention

A catalogue record for this book is available from the British Library

ISBN 978 1 904392 79 8

Electronic ISBN 978 1 84692 566 5

The publisher makes no representation, express or implied, that the dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publisher do not accept any liability for any errors in the text or for the misuse or misapplication of material in this work

Project manager: Gavin Smith, GPS Publishing Solutions, Herts, UK

Series design by Pete Russell, Faringdon, Oxon, UK

Typeset by Mizpah Publishing Services Pvt Ltd, Chennai, India

Printed by Marston Book Services Ltd, Abingdon, Oxon, UK

Contents

Abbreviations vii

SECTION 01 Thyroid 1

- 1 Graves' disease 1
- 2 Hyperthyroidism – multinodular goitre 6
- 3 Thyroid nodule 11
- 4 Sick euthyroid syndrome 16
- 5 Amiodarone and the thyroid 21
- 6 Subclinical hypothyroidism 27
- 7 Thyroid function in early pregnancy 31
- 8 Post-partum thyroid disturbance 35
- 9 Thyrotoxic crisis 39
- 10 Thyroid eye disease 43

SECTION 02 Adrenal 49

- 11 Addison's disease 49
- 12 Autoimmune polyglandular syndromes 54
- 13 The incidental adrenal nodule 59
- 14 Cushing's syndrome 63
- 15 Congenital adrenal hyperplasia 68

SECTION 03 Pituitary 75

- 16 Acromegaly 75
- 17 Prolactinoma 80
- 18 Non-functioning pituitary adenoma 85
- 19 Hypopituitarism: investigation and treatment 90

SECTION 04 Reproductive 95

- 20 Primary amenorrhoea 95
- 21 Secondary amenorrhoea 99
- 22 Polycystic ovarian syndrome – subfertility 104
- 23 Premature ovarian failure 108
- 24 Hirsutism 113
- 25 Erectile dysfunction 119
- 26 Male hypogonadism 125

SECTION 05 Growth 131

- 27 Delayed puberty 131
- 28 Gynaecomastia 136
- 29 Turner's syndrome 142
- 30 Klinefelter's syndrome 147

SECTION 06 Calcium 153

- 31 Primary hyperparathyroidism 153
- 32 Hypocalcaemia 158

SECTION 07 Hypertension 163

- 33 Hypertension – is it endocrine? 163
- 34 Pheochromocytoma 169
- 35 Conn's syndrome 174

SECTION 08 Electrolytes 179

- 36 Hyponatraemia 179
- 37 Hypokalaemia 185
- 38 Hypomagnesaemia 190
- 39 Diabetes insipidus 194
- 40 Spontaneous hypoglycaemia 200

SECTION 09 Therapeutic 205

- 41 Corticosteroid and mineralocorticoid replacement 205
- 42 Neutropaenia on carbimazole 210
- 43 Lithium 214
- 44 Calcium and vitamin D 219
- 45 Oestrogen and progesterone 223
- 46 Thyroid hormone replacement 228

Index 233

Abbreviations

17-OHP	17-hydroxyprogesterone	DI	deiodinase
ACTH	adrenocorticotrophic hormone	DIT	diiodothyronine
ADH	antidiuretic hormone	DITPA	3,5-diiodothyropropionic acid
AECA	anti-endothelial cell antibodies	DOC	deoxycorticosterone
AIDS	acquired immune deficiency syndrome	DST	dexamethasone suppression test
AIT	amiodarone-induced thyrotoxicosis	ECG	electrocardiogram
AITD	autoimmune thyroid disease	ED	erectile dysfunction
ALD	adrenoleukodystrophy	EDTA	ethylenediaminetetraacetic acid
AMI	acute myocardial infarction	EPHESUS	Eplerenone Neurohormonal Efficacy and Survival Study
AMP	adenosine monophosphate	FAI	free androgen index
ANCA	antineutrophil cytoplasmic antibody	FNAC	fine needle aspiration cytology
anti-TPO	antithyroid peroxidase	FSH	follicle-stimulating hormone
APA	aldosterone-producing adenoma	GFR	glomerular filtration rate
APS	autoimmune polyendocrine deficiency syndromes	GH	growth hormone
	autoimmune polyglandular syndromes	GLP	glucagon-like peptide
	adrenergic postprandial syndrome	GMP	guanosine monophosphate
AQP2	aquaporin-2	GnRH	gonadotrophin-releasing hormone
ARR	ratio of plasma aldosterone to plasma renin	GTP	guanosine triphosphate
ATP	adenosine triphosphate	hCG	human chorionic gonadotrophin
AVP	arginine vasopressin	HIV	human immunodeficiency virus
BAH	bilateral adrenal hyperplasia	HLA	human leucocyte antigen
BMD	bone mineral density	HPA	hypothalamic–pituitary–adrenal axis
BMI	body mass index	HRT	hormone replacement therapy
BMR	basal metabolic rate	HU	Hounsfield Unit
CAH	congenital adrenal hyperplasia	ICSI	intracytoplasmic sperm injection
CBZ	carbimazole	IGF	insulin-like growth factor
CC	clomiphene citrate	IPSS	inferior petrosal sinus sampling
CEE	conjugated equine oestrogen	ITU	intensive therapy unit
CI	confidence interval	JNC7	Joint National Committee 7
CRH	corticotrophin-releasing hormone	LH	luteinizing hormone
CT	computed tomography	LOD	laparoscopic ovarian drilling
CTLA-4	cytotoxic T lymphocyte antigen	MDT	multidisciplinary team
DA	dopamine agonist	MEN	multiple endocrine neoplasia
DDAVP	1-desamino-8-d-arginine vasopressin	MIBG	¹²³ I-metaiodobenzylguanidine
DHEA	dehydro-3-epiandrosterone	MIVAT	minimally invasive video-assisted thyroidectomy
DHEAS	DHEA sulphate		

MMAS	Massachusetts Male Aging Study	SCA	silent corticotroph adenomas
MMI	methimazole	SCC	side chain cleavage
MNG	multinodular goitre	SERM	selective oestrogen receptor modulator
MORE	Multiple Outcomes of Raloxifene Evaluation	SERPINA	serine protease inhibitor superfamily member A7
MRI	magnetic resonance imaging	SES	sick euthyroid syndrome
NAION	non-arteritic ischaemic optic neuropathy	SHBG	sex hormone-binding globulin
NANC	non-adrenergic non cholinergic [neurones]	SIADH	syndrome of inappropriate ADH secretion
NEFA	non-esterified fatty acid	SMR	standard mortality ratio
NHANES	National Health and Nutrition Examination Study	SPECT	single photon emission computed tomography
NS	non-significant	SST	Short synacthen test
oGTT	oral glucose tolerance test	T ₃	triiodothyronine
OR	odds ratio	T ₄	thyroxine
PADAM	partial androgen deficiency in ageing men	TBG	thyroxine-binding globulin
PCOS	polycystic ovarian syndrome	TBI	traumatic brain injury
PDE-5	phosphodiesterase-5 inhibitor	TBII	TSH receptor antibodies (TSH binding inhibitory immunoglobulins)
PKA	protein kinase A	TED	thyroid eye disease
POF	premature ovarian failure	TNF	tumour necrosis factor
PPAR- γ	peroxisome proliferator-activated receptor- γ	TPO	thyroid peroxidase
PPTD	post-partum thyroid disturbance	TRAB	TSH receptor antibody
PSV	peak systolic velocity	TRH	thyrotrophin-releasing hormone
PTH	parathyroid hormone	TSH	thyroid-stimulating hormone
PTHrP	parathyroid-related protein	TTR	transthyretin
PTU	propylthiouracil	UFC	urine free cortisol
RALES	Randomised Aldactone Evaluation Study	VLCA	very low chain fatty acids
RR	relative risk	VMA	vanillylmandelic acid
SAGH	subclinical autonomous glucocorticoid hypersecretion	WHI	Women's Health Initiative
SAME	Syndrome of apparent mineralocorticoid excess		

Thyroid

- 01 Graves' disease
- 02 Hyperthyroidism – multinodular goitre
- 03 Thyroid nodule
- 04 Sick euthyroid syndrome
- 05 Amiodarone and the thyroid
- 06 Subclinical hypothyroidism
- 07 Thyroid function in early pregnancy
- 08 Post-partum thyroid disturbance
- 09 Thyrotoxic crisis
- 10 Thyroid eye disease

PROBLEM

01 Graves' Disease

Case History



A previously fit 32-year-old woman notices tremor and heat intolerance. She has lost one and a half stones (9.5 kg) in weight over the past 6 months. You note signs of hyperthyroidism and a diffuse goitre. Her mother is treated for hypothyroidism. The patient smokes 20 cigarettes per day. She and her husband want to start a family in the foreseeable future.

How should she be investigated?

Does she require a thyroid scan?

What is the preferred first line of treatment?

If she has a child, how likely is the child to be affected by Graves' disease?

Background



Thyrotoxicosis occurs in 2% of women and 0.2% of men. In younger people, Graves' disease is by far the commonest diagnosis, with peak onset at 20–40 years. Treatment is with drugs, radioactive iodine or surgery. Thionamide drugs are generally the first line of therapy in young women.^{1,2} They have been used for over 50 years. They are safe and well tolerated. Up to 10% of patients experience mild side effects including urticaria, skin rash, joint pain, altered taste and nausea. These do not usually necessitate stopping the drug. The most serious side effect is agranulocytosis which occurs in less than 0.4%. Patients should always be warned to report skin rash, sore throat or any other untoward side effect, and this warning should be recorded in their notes. If side effects are reported, full blood count and differential should be requested urgently and consideration should be given to stopping the drug.

There are three thionamide drugs—carbimazole (CBZ), methimazole (MMI), and propylthiouracil (PTU). They are similar in their clinical effect. There have been no substantial head-to-head studies comparing them. CBZ is the most commonly used drug in the UK, whereas MMI is used in the USA and in many European countries. PTU is usually used as second line treatment. It has a shorter duration of action and therefore is best given in divided doses. PTU may have free radical scavenging activity, and it is not the drug of first choice before or after radioactive iodine because it may diminish the effectiveness of the latter. Skin rashes may be commoner with MMI—reported rate in trials was 7% for CBZ compared with 12% for MMI.² PTU is the drug of choice in acute severe thyrotoxicosis as it decreases conversion of T_4 to T_3 .

In practice, duration of antithyroid treatment does not appear to be critical. Endocrinologists have all encountered patients who stop taking their drugs after a few months and do not relapse and others who relapse even after prolonged treatment. There is consensus that patients should be treated for at least 6 months, and certainly until serum thyrotropin (TSH) is no longer suppressed and levels of TSH receptor antibodies (TBII) have decreased. Longer treatment may lead to decrease in goitre size, and thus lower risk of relapse. Evidence slightly favours longer than 6 months' treatment; common practice is between 12 and 18 months, and there is no evidence to favour longer treatment.

Most endocrinologists commence patients on high dose and gradually decrease to maintenance dose according to response. Block and replace regimens were based on the hypothesis that antithyroid drugs had immune-modulating and antioxidant properties, and thus may modify the natural history of the disease. Exposure to higher doses of the drug for longer necessitates concurrent thyroid hormone treatment. The two regimens have been compared in 12 studies involving a total of over 1700 patients. The compliance with follow-up varied in these studies. On an intention-to-treat basis, and with follow-up greater than 2 years, relapse rate is just over 50% with either regimen. Higher dose of drug increases risk of side effects. There was no difference in the incidence of agranulocytosis. However, skin rashes were more common in block and replace studies—10% for block and replace vs. 5% for titration (odds ratio [OR] 2.62; 95% confidence interval [CI] 1.20 to 5.75). More people withdrew because of side effects in the block and replace groups.

Treatment with thyroxine following antithyroid drugs was hypothesized to decrease autoantigen exposure and thus lower relapse rate. Three studies have combined thyroxine and low-dose antithyroid drug after initial stabilization with antithyroid drug. No difference in relapse rate was found. In three further studies, antithyroid drug was followed by

a period of thyroxine treatment. In these studies relapse rate was 31% in the thyroxine-treated patients and 29% in those treated with placebo (not significant).

Thyrotoxicosis may temporarily worsen after ^{131}I because of a combination of radiation-induced thyroiditis and increased TBII. Severe exacerbation occurs in less than 1%. Antithyroid drugs are frequently used prior to ^{131}I to achieve more rapid symptom control. There is no real proof that pre-treatment with antithyroid drugs prevents exacerbation of thyrotoxicosis after treatment, but the increase in TBII is less marked, and exacerbations may thus be less severe.³ Resumption of antithyroid drugs after radioactive iodine achieves symptom control but does not alter the outcome.⁴ Antithyroid drugs are generally stopped 4–10 days before therapy and resumed 7 days after.

Genetics of Graves' disease

Graves' disease results from interaction between genetic and environmental factors. Up to 60% of patients have family history of autoimmune thyroid disease (AITD). About a third of first-degree relatives will develop, or have developed, AITD, and around half will be positive for autoantibodies. Concordance rates are higher for monozygotic twins than for dizygotic twins. Genetic influences are thought to account for up to 80% of the susceptibility to Graves' disease.⁵

The human leucocyte antigen (HLA) complex located at chromosome 6p21 has three classes of antigen:

- class I—HLA-A, B and C
- class II—HLA DP, DQ and DR
- class III—complement, tumour necrosis factor (TNF)- α , heat shock protein-70 and other immune regulatory genes.

This is a highly polymorphic region of the genome, conferring susceptibility to a range of diseases. HLA-DR3 is the most useful marker. Among patients with Graves' disease 40–50% are HLA-DR3 positive, compared with 15–30% of the general population. Recent studies have identified associations with other HLA alleles, most notably DQA1*0501. HLA is probably important in all ethnic groups, but the precise associations in non-Caucasians differ from the above. Cytotoxic T lymphocyte antigen-4 (CTLA-4), located at chromosome 2q33, is a costimulatory molecule involved in interaction between T lymphocytes and antigen-presenting cells. At least four polymorphisms have been identified and confer susceptibility to autoimmune endocrine disease.⁶ Together, HLA antigens and CTLA-4 confer around half the susceptibility to Graves'. Other candidate genes include immune regulatory genes, such as the vitamin D receptor, TSH receptor and thyroglobulin.

Recent Developments



- 1 Wang *et al.*⁷ have shown that the A/G polymorphism at position 40 in exon 1 of CTLA-4 may be a marker for relapse after antithyroid drug therapy. Early identification of patients liable to relapse may allow us to target definitive treatment early.
- 2 The Nurses' Health Study⁸ followed 115 109 women aged 25–42 over 12 years. The incident diagnosis of Graves' was 4.6 per 1000. Smoking was a risk factor (hazard ratio




Fig. 1.1 Use of antithyroid drugs. *Scan with technetium-99m pertechnetate or iodide. ATD = antithyroid drugs; CBZ = carbimazole; MMI = methimazole; PTU = propylthiouracil; Tg = thyroglobulin; TPO = thyroid peroxidase; TRAB = TSH receptor antibodies.

1.93). Obesity was associated with lower risk of Graves'—hazard ratio for individuals with body mass index (BMI) greater than 30 kg/m² was 0.68 (95% CI 0.49 to 0.92).

- 3 Colour Doppler sonography may be useful in diagnosis of thyroid disorders. This is a safe, non-invasive technique to assess blood flow in the thyroid arteries. Results correlate highly with thyroid volume and function. In a preliminary study,⁹ thyroid blood flow at baseline was highly correlated with outcome after 14 months of antithyroid drug therapy. Relapse could be predicted with a sensitivity of 71% and specificity of 100%.

Conclusions



Initial investigations should include thyroid hormone, TSH and thyroid antibodies, including TBII. Full blood count and liver tests should be requested at baseline and at intervals in patients taking antithyroid drugs (Figure 1.1). Thyroid scanning is not routinely warranted unless there is doubt about the diagnosis. Antithyroid drug treatment is usually the first line treatment. Radioactive iodine has been increasingly used in recent years. There is no evidence of teratogenicity. Obviously, it is absolutely contraindicated during pregnancy and most endocrinologists would avoid its use within 6–12 months of conception. The above patient should not be overly concerned about the implications of the disease for her children although, if female, they will inherit a roughly one in three lifetime chance of developing AITD.

Further Reading



- 1 Cooper DS. Antithyroid drugs. *N Engl J Med* 2005; **352**: 905–17.
- 2 Abraham P, Avenell A, Watson WA, Park CM, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism (Review). *Cochrane Library* 2005; **3**: 1–48.
- 3 Andrade VA, Gross JL, Maia AL. Serum thyrotropin-receptor autoantibody levels after ¹³¹I therapy in Graves' patients: effect of pretreatment with methimazole evaluated in a prospective, randomized study. *Eur J Endocrinol* 2004; **151**: 467–74.
- 4 Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L. Resumption of methimazole after ¹³¹I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomised clinical trial. *Eur J Endocrinol* 2003; **149**: 485–92.
- 5 Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. *Endocr Rev* 2003; **24**: 694–717.
- 6 Vaidya B, Pearce S. The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. *Eur J Endocrinol* 2004; **150**: 619–26.
- 7 Wang PW, Liu RT, Juo SHH, *et al*. Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves' hyperthyroidism after antithyroid withdrawal. *J Clin Endocrinol Metab* 2004; **89**: 169–73.
- 8 Holm I, Manson JE, Michels KB, Alexander EK, Willett WC, Utiger RD. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. *Arch Intern Med* 2005; **165**: 1606–11.
- 9 Saleh A, Cohnen M, Fürst G, Mödder U, Feldkamp J. Prediction of relapse after antithyroid drug therapy of Graves' disease: value of color Doppler sonography. *Exp Clin Endocrinol Diabetes* 2004; **112**: 510–13.